eFT508

June 14, 2018

First Patient Dosed in Phase 2 Trial of eFT508 for Aggressive Non-Hodgkin’s Lymphoma

News

The Phase 1/2 clinical trial evaluating eFT508 for the treatment of relapsed or refractory non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL) has dosed the first patient in its Phase ... Read more

March 14, 2017

FDA Gives Orphan Drug Status to eFT508 for Treating Diffuse Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to eFT508, which treats diffuse large B-cell lymphoma (DLBCL) by inhibiting proteins associated with the disease. The designation is ... Read more